Adaptive Biotechnologies Corp
NASDAQ:ADPT
Adaptive Biotechnologies Corp
Capital Expenditures
Adaptive Biotechnologies Corp
Capital Expenditures Peer Comparison
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
Capital Expenditures
-$9.3m
|
CAGR 3-Years
33%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Capital Expenditures
-$1.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-18%
|
|
Danaher Corp
NYSE:DHR
|
Capital Expenditures
-$1.4B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-10%
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Capital Expenditures
-$99.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-2%
|
|
Agilent Technologies Inc
NYSE:A
|
Capital Expenditures
-$312m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-6%
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Capital Expenditures
-$649m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-22%
|
See Also
What is Adaptive Biotechnologies Corp's Capital Expenditures?
Capital Expenditures
-9.3m
USD
Based on the financial report for Mar 31, 2024, Adaptive Biotechnologies Corp's Capital Expenditures amounts to -9.3m USD.
What is Adaptive Biotechnologies Corp's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
0%
Over the last year, the Capital Expenditures growth was 42%. The average annual Capital Expenditures growth rates for Adaptive Biotechnologies Corp have been 33% over the past three years .